



## **NORGINE'S PETER MARTIN IS THE NEW CHAIR OF THE EUROPEAN MEDICINES GROUP**

27 June 2005

Peter Martin, Chief Operating Officer at Norgine, an independent, successful European specialty pharmaceutical company, has been elected this month to be Chair of the European Medicines Group (EMG).

The EMG is the UK voice of research-driven pharmaceutical companies whose headquarters are in continental Europe, and who develop and supply prescription medicines to the NHS.

Commenting at the start of his one year Term of Office, Peter said; "I'm delighted to chair the EMG. We have an important role in ensuring that patients, carers and policy makers understand the important contribution of the European pharmaceutical industry to the UK. We must ensure that UK patients not only have access to the most effective medicines based on clinical need, not the ability to pay, that is currently enjoyed by patients in other European countries, and also have access to medicines information from appropriate sources, including the pharmaceutical industry".

Mr Martin joined Norgine in May last year and since then has also been appointed to The Association of the British Pharmaceutical Industry (ABPI) Board of Management. Although the EMG is independent of the ABPI, the two organisations work together on common industry issues.

**ENDS**

## **Notes to editor**

### Norgine

Norgine is an independent, successful European specialty pharmaceutical company that has been established for almost 100 years and has a presence in all the major European markets. In 2004 Norgine's sales were €155 million, the 18<sup>th</sup> consecutive year of double-digit growth. The company employs 900 people, of which 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. Movicol® for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy, Fivasa® for the treatment of inflammatory bowel disease and Oramorph® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has nine products at various stages of clinical development including NRL994, a bowel preparation product. A European submission for NRL994 has already been filed and the company expects to submit an NDA in 2005.

Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is [www.norgine.com](http://www.norgine.com)

### European Medicines Group

In addition to Norgine, EMG members include A Menarini Pharmaceuticals, Altana Pharma, Bayer, Boehringer Ingelheim, Elan Pharma, Fournier Pharmaceuticals, LEO Pharma, Merck Pharmaceuticals, Novartis Pharmaceuticals, Novo Nordisk, Organon Laboratories, Roche Products, Sanofi Aventis, Schering Healthcare, Schwarz Pharma, Serono, Servier Laboratories, Solvay Healthcare and UCB Pharma. Many members of the EMG are also members of the ABPI.

### **For further information, please contact:**

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: [ppay@norgine.com](mailto:ppay@norgine.com)

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: [lblakeborough@chapterfive.co.uk](mailto:lblakeborough@chapterfive.co.uk)